Project Grant K22CA289144
Award Date 9/11/25
Completion Date 8/31/28
Dollars Obligated $202K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Utah, USA
Similar Awards
- This $627,422 Project Grant award from the National Cancer Institute under the Cancer Treatment Research (CFDA 93.395) program supports research by the Regents of the University of Michigan to engineer commensal bacteria that can neutralize the colibactin genotoxin produced by certain gut bacteria associated with increased colorectal cancer risk. The key products and services to be delivered under this 5-year grant include: 1) Further optimization of the surface display of the anti-toxin...
- The National Cancer Institute (NCI) has awarded a $727,904 Cooperative Agreement to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, under the Cancer Biology Research program (CFDA 93.396). The purpose of this 23-month award, with a start date of August 11, 2025, is to engineer probiotic bacteria (E. coli Nissle 1917) to identify precancerous lesions, characterize novel stage-specific immune targets, and design immunomodulatory...
- This $2,864,671 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Regents of the University of Michigan is focused on developing a novel strategy to enzymatically inhibit colibactin, a procarcinogenic metabolite from enteric bacteria associated with colorectal cancer (CRC). The objectives are to: (1) create engineered microbes that can deliver the colibactin inactivation protein ClbS to safely and effectively neutralize colibactin in the gut,...
- The federal Project Grant award of $697,763 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by The University of Texas MD Anderson Cancer Center to decipher the critical determinants of how the Fusobacterium nucleatum (FN) bacteria colonizes the colorectal cancer (CRC) tumor microenvironment and contributes to disease progression. The project aims to gain mechanistic insights into how this oral bacteria homes to and persists within the CRC tumor, as...
- This Project Grant award of $600,499.00 from the National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), supports research conducted by The Trustees of Columbia University in the City of New York (Health Sciences Division) to investigate the role of the Fusobacterium nucleatum (FN) bacterium and the Annexin A1 (ANXA1) protein as potential biomarkers in colorectal cancer oncogenesis. The key objectives of this 5-year project are to: (I) mechanistically investigate...
- This federal Project Grant award of $606,839.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to identify gut microbiota that actively deplete intestinal amino acids and evaluate how they affect the tumor microenvironment and cancer progression. The primary awardee is Weill Medical College of Cornell University, a leading academic medical institution with expertise in biomedical research and translational science. The project aims to...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Stanford University to investigate how the human gut microbiome can be modulated to enhance immune responses against cancer, with a focus on improving the efficacy of cancer immunotherapy treatments. The $179,988 award, which runs from January 1, 2025 to December 31, 2026, aims to identify bacterial genes and functions that can boost the body's immune response to immune...
- This $1,355,273 Project Grant was awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to the Regents of the University of Michigan. The grant funds the development of two complementary approaches to inhibit the production of the bacterial metabolite colibactin, which has been linked to colorectal cancer and microbiome dysbiosis. The first approach involves enzymatic inactivation of colibactin through...
- This Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), focuses on exploring the role of bacterial-derived small molecules in improving immunotherapy response rates and overall survival for non-small cell lung cancer patients. The $540,288 award to the University of Florida aims to test the central hypothesis that specific bacteria produce small molecules that can augment the efficacy and mitigate the toxicity of immune...
- This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...